Sanofi Takes Options on Oxford Biomedica's Gene Therapies
LONDON – Oxford Biomedica plc said that Sanofi SA is taking up its options on two gene therapy products for treating retinal disease, triggering a $3 million milestone and providing the impetus for a placing and open offer to raise up to £16 million (US$25 million).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter